Michele Cucullu is Managing Director of Private Investments at Bayshore and oversees the family office’s private equity investments and the foundation’s CNS investment program. Michele has over two decades of investment experience and, prior to her current role, was Director of Private Equity at the University of California for more than a decade. Earlier, she was on the Investment Team at Caltech.
Sonya Bhatia, PhD, is a Director of Life Science Investments, CNS at Bayshore where she focuses on biotechnology and healthcare investments in Central Nervous System (CNS) disorders including Parkinson’s disease, Autism Spectrum Disorders (ASD) and Bipolar Disease. Her work spans therapeutics, diagnostics, and digital health, with a focus on advancing treatments and improving patient care.
Before joining Bayshore, Sonya was Vice President on the Goldman Sachs Life Sciences Investing team, where she helped build the platform and supported investments across oncology, immunology and rare disease. She began her career on the Biotechnology Equity Research team at Goldman Sachs.
Sonya holds a PhD in Genetics from Harvard University and a BA in Neuroscience from Smith College.
Hilary Wang, Investment Associate, focuses on the Quests investment programs at Bayshore. Within the CNS Quest, Hilary’s investment focus includes Parkinson’s Disease, Autism Spectrum Disorders, and Bipolar Disease. Hilary joined Bayshore in May 2022 and graduated from Brown University.
Maria Kousi, PhD, is Director of Life Science Investments at a Private Family Office in Palo Alto, CA since October 2024. Maria has trained in human genetics and neuroscience, with the goal to understand the genetic mechanisms leading to neurological diseases.
Maria was at Third Rock Ventures (TRV) from 2018 to 2024, doing early company creation at the intersection of genetics and neuroscience. She has led the efforts on the creation of companies offering genetics-based diagnostic solutions, individualized treatments to children with neurological diseases and therapeutic approaches in psychiatric disease under a precision medicine paradigm.
Prior to TRV, Maria was a senior scientist at MIT and Harvard, focusing on the elucidation of genetic mechanisms leading to late-onset neurodegenerative diseases. She trained as a postdoctoral fellow at Duke University, leading the efforts on the clinical diagnosis of children with neurological disease using WES and functional dissection of variant effect in surrogate animal disease models. She holds a PhD in human genetics of childhood onset progressive myoclonic epilepsies from the University of Helsinki, Finland, and a master’s degree in human genetics from the same institution.